March 18, 2019
NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark  this link  for your convenience.

NRG Oncology Trial Suggests Adding Docetaxel-based Chemotherapy to Standard Treatment Should be Considered for Men with High-Risk Prostate Cancer.

Read more

Seth A. Rosenthal, MD



NRG-BR004: Activation Date: March 12, 2019 (posted to CTSU)




NRG-GY003: Amendment 10; version date: February 28, 2019 (posted on CTSU)




NRG-GI002: E-mail Blast (posted to CTSU)


2. CPC

Alliance protocol A211401 “Reducing Surgical Complications In Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes” is open to patient entry and available to NRG Oncology sites. Protocol documents are located on the CTSU website. Please enroll eligible participants to this trial (NRG Oncology Study Champion: Simon Lo, MD)


NRG-GI006: Protocol overview slides are available on the Education and Promotion tab of the CTSU protocol website.


NRG-GY004: Data Freeze - March 2019

NRG-GY004 is maturing for the final analysis. Please ensure all data is up to date (including follow-up information), and all queries are answered. We expect to start the final analysis in March 2019.  We will provide the results of this important study to you as soon as possible. If you have any questions please contact Sandy Dascomb at:


NRG-GY007: Currently accruing to the Phase II portion Read more


Form TR for Biospecimens Shipped to NRG Biospecimen Bank-Columbus Read more


Biospecimen Bank-Columbus & SDMC Undergoing Refurbishment Read more


The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003, and NRG-CC004. Space is limited so register now and reserve your seat.  The next webinar training is scheduled for Wednesday, April 10.


NRG Oncology Trial Suggests Adding Docetaxel-based Chemotherapy to Standard Treatment Should be Considered for Men with High-Risk Prostate Cancer

According to the American Cancer Society, prostate cancer is the second most common cause of cancer-related death among men in the United States in 2018. Currently, the standard of care treatment for high-risk, localized prostate cancer is a combination of radiotherapy (RT) and long-term (24-36 month) androgen suppression (AS). Researchers theorized that adding adjuvant docetaxel, a cytotoxic chemotherapy drug, to the standard of care RT and long-term AS treatment could potentially improve overall survival and clinical outcomes for men with localized, high-risk prostate cancer. Read more

NRG Oncology is pleased to report the scientific articles and abstracts that have appeared or have been presented during the previous week. This publications report includes links, when available, to the article, PubMed abstract, or association abstract.


Rosenthal SA, Hu C, Sartor O, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Horwitz EM, Raben A, Peters CA, Feng FY, Shipley WU, Sandler HM. Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. J Clin Oncol. 2019 Mar 12: JCO1802158. doi: 10.1200/JCO.18.02158. [Epub ahead of print] PubMed PMID: 30860948. Read more



Please note the following upcoming meeting and abstract submission deadline dates


Upcoming Meetings

American Association for Cancer Research (AACR); Mar 29 - Apr 3, 2019; Atlanta, GA

European Society for Radiotherapy and Oncology (ESTRO); Apr 26-30, 2019; Milan, Italy

Society of Surgical Oncology (SSO); Mar 27-30, 2019; San Diego, CA

St. Gallen Breast Cancer Conference (SG-BCC); Mar 20-23, 2019; Vienna, Austria

Upcoming Abstract Submission Deadlines

ESMO Breast Cancer Annual Congress; May 2-4, 2019; Berlin, Germany; LBA deadline Apr 1, 2019 noon CEST (Central European Summer Time)

European Society of Gynaecolocial Oncology (ESGO) Biennial; Nov 2-5, 2019; Athens, Greece; due to publications committee Apr 19, 2019; meeting submission deadline May 3, 2019

International Society for Quality of Life Research (ISOQOL); Oct 20-23, 2019; San Diego, CA; due to publications committee Mar 26 2019; meeting submission deadline Apr 8, 2019

Radiological Society of North America (RSNA); Dec 1-6, 2019; Chicago, IL; due to publications committee Mar 27 2019; meeting submission deadline Apr 10, 2019

Western Association of Gynecologic Oncologists (WAGO); Jun 12-15, 2019; Huntington Beach, CA; meeting submission deadline Mar 25, 2019

NRG Oncology is proud to be an active participant of #CancerMoonShot.
This message was sent from to
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103

Update Profile/Email Address | Forward Email | Report Abuse